Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -4.35% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $3.09 today, the market must believe free cash flow compounds -34.1%/yr for a decade (off $75M normalized FCF).
2-stage DCF · 0.06B shares · net debt -$65M
mean -245.5% · volatility σ 170% · implied rate exceeded in 0/2 yrs
Central path = implied -34.1%/yr growth; shaded band = ±1σ (170%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.4M 100.0% | $80.0M 100.0% | $250.0M 100.0% | $40.9M 100.0% | $37.4M 100.0% | $171.1M 100.0% | $104.4M 100.0% | $7.6M 100.0% | $10.1M 100.0% | $14.2M 100.0% |
| Research & Development | $134.7M 333.6% | $127.4M 159.2% | $92.2M 36.9% | $60.8M 148.5% | $73.8M 197.2% | $108.8M 63.6% | $119.7M 114.7% | $64.9M 851.9% | $62.3M 614.3% | $42.2M 297.1% |
| Selling, General & Admin | $37.5M 93.0% | $35.9M 44.9% | $35.8M 14.3% | $31.0M 75.7% | $37.2M 99.5% | $35.0M 20.4% | $36.3M 34.8% | $33.8M 443.7% | $19.7M 194.8% | $13.3M 93.3% |
| Total Operating Expenses | $172.2M 426.6% | $163.3M 204.1% | $128.0M 51.2% | $91.7M 224.3% | $111.0M 296.8% | $143.7M 84.0% | $156.1M 149.5% | $98.7M 1295.6% | $82.0M 809.1% | $55.5M 390.4% |
| Operating Income | -$131.8M -326.6% | -$83.3M -104.1% | $122.0M 48.8% | -$50.8M -124.3% | -$73.6M -196.8% | $27.4M 16.0% | -$51.7M -49.5% | -$91.1M -1195.6% | -$71.9M -709.1% | -$41.3M -290.4% |
| Other Income (Expense), net | $12.3M 30.4% | $18.9M 23.7% | $11.7M 4.7% | $4.4M 10.9% | $2.4M 6.5% | $9.4M 5.5% | $8.1M 7.7% | $2.6M 34.5% | $1.2M 11.5% | $1.2M 8.1% |
| Pretax Income | -$119.6M -296.2% | -$64.3M -80.4% | $133.7M 53.5% | -$46.4M -113.4% | -$71.2M -190.3% | $36.7M 21.5% | -$43.6M -41.8% | -$88.5M -1161.1% | -$70.7M -697.6% | -$40.1M -282.3% |
| Income Tax Expense | $144K 0.4% | $665K 0.8% | $1.4M 0.6% | $16K 0.0% | — | — | — | -$180K -2.4% | — | $52K 0.4% |
| Net Income | -$119.7M -296.5% | -$65.0M -81.3% | $132.3M 52.9% | -$46.4M -113.4% | -$71.2M -190.3% | $36.7M 21.5% | -$43.6M -41.8% | -$88.3M -1158.8% | -$70.7M -697.6% | -$40.2M -282.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.04 | $-1.13 | $3.08 | $-1.21 | $-1.89 | $0.99 | $-1.21 | $-2.75 | — | — |
| EPS (Diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 | — | — |
| Weighted Avg Shares (Basic) | 58.7M | 57.7M | 43.0M | 38.4M | 37.7M | 37.1M | 35.9M | 32.1M | — | — |
| Weighted Avg Shares (Diluted) | 58.7M | 57.7M | 44.6M | 38.4M | 37.7M | 37.3M | 35.9M | 32.1M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
1/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$135M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -61%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-18
Where each multiple sits in its own 11-yr range · 18th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 851.9 | 114.7 | 63.6 | 197.2 | 148.5 | 36.9 | 159.2 | 333.6 |
| SG&A | 443.7 | 34.8 | 20.4 | 99.5 | 75.7 | 14.3 | 44.9 | 93.0 |
| Operating Income | -1195.6 | -49.5 | 16.0 | -196.8 | -124.3 | 48.8 | -104.1 | -326.6 |
| Income Tax | -2.4 | — | — | — | 0.0 | 0.6 | 0.8 | 0.4 |
| Net Income | -1158.8 | -41.8 | 21.5 | -190.3 | -113.4 | 52.9 | -81.3 | -296.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VYGR: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| VYGR | $182M | — | — | 4.5× | -49.5% | — | -297% | -61.1% | -61.1% | — | 133 |
Peers = companies sharing VYGR's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.